文献速递造血干细胞移植与细胞治疗

MEK/ERK与PI3K/AKT双通路抑制可预防肺GVHD并抑制静脉周围炎和细支气管炎

Dual inhibition of the MEK/ERK and PI3K/AKT pathways prevents pulmonary GVHD suppressing perivenulitis and bronchiolitis.
PubMed 文献 · Blood Adv · 2023-01-01

研究对45例因肺GVHD接受肺移植的allo-HSCT受者肺标本进行病理评估,并在小鼠肺GVHD模型中验证。结果显示细支气管炎和胸膜下血管周围炎伴B细胞、单核细胞和T细胞聚集;cobimetinib改善小鼠生存并减轻细支气管炎,曲美替尼联合taselisib双通路抑制较单药或对照改善小鼠生存。

要点

  • 肺GVHD病理特征为细支气管炎和胸膜下血管周围炎,伴B细胞、单核细胞和T细胞聚集。
  • cobimetinib而非曲美替尼改善小鼠肺GVHD生存率并减轻细支气管炎。
  • 曲美替尼联合taselisib双通路抑制较单药或对照改善小鼠生存率。

核心结论

  • MEK/ERK和PI3K/AKT通路激活介导的血管周围炎和细支气管炎是肺GVHD的关键环节,可能成为人类肺GVHD的新治疗靶点。

研究设计与样本

  • 对45例因肺GVHD接受肺移植的allo-HSCT受者肺标本进行病理评估。
  • 采用C57BL/6至B10.BR小鼠骨髓细胞和脾细胞移植建立小鼠肺GVHD模型。

主要发现

  • 患者肺病理表现为细支气管炎和胸膜下血管周围炎,细支气管周围有B细胞、单核细胞和T细胞聚集。
  • 小鼠肺GVHD模型中也可见细支气管炎、血管周围炎和支气管周围巨噬细胞聚集。
  • cobimetinib改善小鼠生存率,减轻细支气管炎,改善气道阻力和肺顺应性,并在体外抑制B细胞活化和单核细胞产生肿瘤坏死因子α;曲美替尼或他克莫司未显示这些抑制作用。
  • cobimetinib抑制PI3K/AKT信号激活,从而抑制B细胞和单核细胞。
  • 曲美替尼联合PI3K抑制剂taselisib双通路抑制在体外强烈抑制B细胞活化,较对照或曲美替尼、taselisib单药改善小鼠生存率。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Patients with pulmonary graft-versus-host disease (pGVHD) have a poor prognosis after allogeneic hematopoietic stem cell transplantation (allo-HSCT). Furthermore, pGVHD pathogenesis is not fully elucidated in humans, and currently available immunosuppressants are inadequately effective. We performed pathologic evaluation of lung specimens from 45 allo-HSCT recipients with pGVHD who underwent lung transplantation. Patient pathology was characterized by bronchiolitis and subpleural perivascular inflammation, with B-cell, monocyte, and T-cell accumulation around bronchioles. Bronchiolitis, perivascular inflammation, and peribronchial macrophage aggregation were also identified in a murine pGVHD model after transplant of bone marrow cells and splenocytes from C57BL/6 to B10.BR mice. Among mitogen-activated protein kinase kinase (MEK) inhibitors, cobimetinib, but not trametinib, improved survival rates. Cobimetinib attenuated bronchiolitis, improved airway resistance and lung compliance in the mice, and suppressed activation of B cells and tumor necrosis factor α production by monocytes in vitro; these features were not suppressed by trametinib or tacrolimus. Furthermore, cobimetinib suppressed activation of phosphatidylinositol 3-kinase/protein kinase B (PI3K/AKT) signaling, resulting in B-cell and monocyte suppression. Dual inhibition of the MEK/extracellular signal-regulated kinase (ERK) and PI3K/AKT pathways using a combination of trametinib and the PI3K inhibitor taselisib strongly suppressed B-cell activation in vitro and improved mouse survival rates compared with vehicle or monotherapy with trametinib or taselisib. Imaging mass cytometry of human pGVHD revealed that T cells around bronchioles were positive for phosphorylated ERK, whereas B cells were positive for phosphorylated AKT. Thus, perivascular inflammation and bronchiolitis mediated by activation of the MEK/ERK and PI3K/AKT pathways are essential for pGVHD and represent a potential novel therapeutic target in humans.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Muranushi H, Shindo T, Chen-Yoshikawa TF, et al. Dual inhibition of the MEK/ERK and PI3K/AKT pathways prevents pulmonary GVHD suppressing perivenulitis and bronchiolitis. Blood Adv. 2023. PMID: 35468620. doi:10.1182/bloodadvances.2021006678

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。